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Abstract: Delivery of chemotherapeutic drugs to tumours by reformulation as nanoparticles has often 
been proposed as a means of facilitating increased selective uptake, exploiting the increased 
permeability of the tumour vasculature. However realisation of this improvement in drug delivery in 
cancer patients has met with limited success. We have compared tumour uptake of soluble Tc99m-
pertechnetate and a colloid of nanoparticles with a Tc99m core, using both intravenous and intra-
arterial routes of administration in a rabbit liver VX2 tumour model. The radiolabelled nanoparticles 
were tested both in untreated and cationised form. The results from this tumour model in an internal 
organ show a marked advantage in intra-arterial administration over the intravenous route, even for 
the soluble isotope. Tumour accumulation of nanoparticles from arterial administration was 
augmented by cationisation of the nanoparticle surface with histone proteins, which consistently 
facilitated selective accumulation within microvessels at the periphery of tumours. 
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Abstract: 
 Delivery of chemotherapeutic drugs to tumours by reformulation as 
nanoparticles has often been proposed as a means of facilitating increased selective 
uptake, exploiting the increased permeability of the tumour vasculature. However 
realisation of this improvement in drug delivery in cancer patients has met with 
limited success. We have compared tumour uptake of soluble Tc99m-pertechnetate 
and a colloid of nanoparticles with a Tc99m core, using both intravenous and intra-
arterial routes of administration in a rabbit liver VX2 tumour model. The radiolabelled 
nanoparticles were tested both in untreated and cationised form. The results from 
this tumour model in an internal organ show a marked advantage in intra-arterial 
administration over the intravenous route, even for the soluble isotope. Tumour 
accumulation of nanoparticles from arterial administration was augmented by 
cationisation of the nanoparticle surface with histone proteins, which consistently 
facilitated selective accumulation within microvessels at the periphery of tumours. 
Keywords: Nanoparticle delivery, arterial administration, vascular permeability, 
imaging isotope, liver cancer. 
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Introduction 
The growth of a tumour in a host organ is accompanied by angiogenesis that 
not only markedly changes the architecture of the vascular network [1-3], but also 
considerably increases access to the extravascular space due to the increased 
permeability of the new vessels [4]. This provides opportunity for improvement in 
delivery of chemotherapeutic agents by reformulation into nanoparticulate 
composites that can extravasate into tumours [5]. 
Nanoparticles tend to be rapidly removed from the circulation by the 
phagocytic cells resident in the liver and spleen (reticuloendothelial system; RES), 
but it has been suggested they can also escape through the highly fenestrated walls 
of tumour capillaries and distribute within the tumour matrix [6]. Extravasation of 
macromolecules into tumours has been known for many years, visualised earlier for 
example by increased dye uptake [7], and this has become known as the enhanced 
permeability and retention (EPR) effect [8]. Thus it is the object of much current 
research to exploit tumour EPR by administration of nanoparticulate formulations of 
cytotoxic agents [9, 10]. It should be noted however that while most preclinical 
studies have been done in animal models of subcutaneously implanted tumours, data 
on extravasation, penetration and accumulation of nanoparticles in tumours of 
internal organs, like many of those cancers occurring in human patients, is especially 
lacking. In this context, it is also important to explore different routes of administration, 
especially intra-arterial instillation. 
In this report we have investigated tumour uptake of imaging radioisotope in 
the form of a soluble compound (Tc99m-pertechnetate) and compared this with 
uptake of a nanoparticulate isotope preparation. Further, we have performed these 
imaging investigations in a rabbit tumour model of liver cancer, where we could study 
biodistribution inside this internal organ after intra-venous and intra-arterial 
administration of both types of agents. 
*Manuscript
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Materials and Methods: 
Nanoparticle synthesis 
Carbon-caged Tc-99m, (FibrinLite; FL) was synthesised as described in detail in US 
patent 8,778,300 [11]. The nanoparticle technology employed was based on Technegas™, a 
radioactive aerosol preparation developed for diagnostic ventilation imaging of the lungs [12].  
Vapour-phase particle sizing using an electrostatic particle classifier (TSI Inc, MN USA) 
showed the aerosol comprises log-normal distributed particles with the bell curve centred on 
150-350 nm, and negligible particles below 100 nm or above 400 nm. Electron microscope 
characterisation shows metallic platelets surrounded by multiple lamellae of carbon [13]. 
Using the patented FL process, sodium Tc99m-pertechnetate solution was loaded into a 
graphite crucible and after removing sodium chloride by sublimation at 1650ºC, the isotope 
was plasma ablated at 2750ºC into an argon gas stream. Aerosol nanoparticles were 
collected into water (6.0 mL) from the gas stream using a Browitt sonicating precipitator [14], 
thus producing a stable colloidal dispersion of FL. The radioactive FL colloid was filtered 
through a 450 nm hydrophilic membrane (mixed cellulose ester (MCE); Millipore) before use. 
A typical preparation of FL contained approximately 5 µg/mL of graphitic carbon with a 
specific activity of 20 MBq/µg. FL nanoparticles are highly stable, and integrity of the isotope 
encapsulation is preserved under standard autoclave conditions of 20 min at 120ºC. 
Coating of FL with polycations 
We have previously shown using a membrane filtration model and microwell binding 
assays that polycations such as polylysine bind to the surface of FL with high affinity [15]. We 
have proposed [15] that this is mediated by multi-site pi-cation interactions [16,17] between 
the positively charged amino groups of the amino acid side-chains and the pi-electrons of the 
planar carbon rings of the graphite surface. The histone family of proteins are also polycations 
due to a high content of arginine and lysine residues [18] and binding of these proteins to FL 
can only be reversed with strong ionic detergents such as sodium dodecyl sulfate [19]. 
Binding of these polycations to FL is also stable under in vivo conditions, as shown by our 
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previous imaging studies of polycation coated FL in the capillary network of rabbit lungs 
[15,19]. 
In the present study, FL was treated with a selection of polycations, including 
protamine sulphate (PS; 20 µg/mL), poly-D-lysine (PDL; 6 µg/mL) and calf thymus histone 
proteins (CTH; 10 µg/mL), all from Sigma Aldrich, Castle Hill, Sydney. FL was buffered with 
0.5 mM Tris acetate buffer (pH 7.2) before addition of polycations, which were then allowed to 
bind for 1 h at 20ºC before use of the coated FL preparations in animal imaging experiments. 
Rabbit VX2 liver tumour model 
All rabbit procedures adhered to the National Health and Medical Research Council’s 
Animal Welfare Code for the appropriate use of animals for scientific purposes (Australian 
Government, 7
th
 Ed. 2004), and the experimental protocols were approved by the Australian
National University (ANU) Animal Ethics Committee. New Zealand white rabbits were used at 
a minimum age of four months, when their body weight was an average of 3.8 +/- 0.6 kg (n = 
23) and their livers weighed 117 +/- 24 grams. The transplantable rabbit VX2 tumour [20] was
a kind gift of Dr J Geschwind (Johns Hopkins University, Baltimore, USA) and was maintained 
as a serial transplant on the hind limbs. Liver implants of tumour tissue were made at a single 
site in one lobe by keyhole surgery under ventilation anaesthesia with isoflurane, and allowed 
to grow for 18 days before use of the rabbit in imaging experiments. At this stage of growth 
the tumour had a diameter of less than 2 cm, and the oblate ellipsoid of tumour was still 
completely contained within the liver lobe and did not involve the body wall or other organs. 
Macroscopically, the tumour usually had a necrotic centre, with an enhanced blood supply 
evident in an actively growing vascularised peripheral zone. Measurements of the shortest 
and longest axes of the excised tumours were used to estimate the volume, which averaged 
2.9 +/- 1.9 cm
3
 (n = 41).
Biodistribution studies of radiolabelled materials in rabbits 
Rabbit imaging studies were done under ventilation anaesthesia with isoflurane using 
either a Siemens Diacam gamma camera or a GE Hawkeye Infinia SPECT-CT camera. For 
imaging studies with intravenous administration, sodium Tc99m-pertechnetate or FL colloid (3 
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mL, 130-170 MBq) was injected in an ear vein. Intrahepatic artery instillations of 
pertechnetate and FL were performed by catheterisation of the cystic artery and using pulses 
of the isotope material (total 5 mL, 130-170 MBq) interspaced with normal hepatic artery 
blood flow, so as to disperse the isotope throughout the liver with close to normal blood 
perfusion conditions [21]. Symporter uptake of pertechnetate in organs and tumours was 
tested for by prior intravenous injection of sodium perchlorate (3 mg/kg; Sigma Aldrich) [22]. 
Heparan sulphate mediated endothelial uptake of cationised FL was tested for by prior 
intravenous injection of competing polyions [19]: PS (1 mg/kg), PDL (1 mg/kg), and heparin (1 
mg/kg; Sigma Aldrich), or by prior treatment of the rabbit for 1 h with intravenous injection of 
heparinase type III (10 units; Sigma Aldrich) [19]. 
Static 5 min acquisitions were made on a 1024 x 1024 matrix approx 10 min after 
administration of the imaging agent and again after one hour. After completion of imaging, the 
rabbit was euthanized by lethal injection while still under anaesthesia, and the liver was 
excised after tying off all vessels to prevent leakage of isotope. The excised liver was then 
imaged separately using a 5 min acquisition on a 1024 x 1024 matrix, and utilising a zoom 
function (e.g. 3.2x or 4x). Counts registered in the acquisitions were corrected for the 
background activity of the corresponding field, and the corrected counts were used for 
calculation of the percentage activity in the liver compared to the carcass. Tumour uptake 
data was limited to tumours that had grown to at least 1.0 cm
3
 and located in the same lobe of
the liver in each rabbit. Activity levels in the images shown in the Figures were assigned false 
colours using the A2 colours in the Siemens Diacam gamma camera or the XT21 Brain1 
colours in the Hawkeye Infinia SPECT/CT colour maps respectively. 
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Results 
Biodistribution of soluble Tc99m-Pertechnetate 
Intravenous injection of soluble Tc99m-pertechnetate produced images of circulating 
radioactivity distributed according to the blood perfusion of the main organs (heart, lungs, liver 
and spleen) but also with some accumulation in the kidneys and thyroid at 1 h post-injection 
(Fig 1A). The excised liver 1 h post-injection retained only 15.8% of the total radioactivity (see 
Table 1) and the gamma camera image showed it was generally dispersed throughout the 
lobes of the organ. When Tc99m-pertechnetate was instilled in the hepatic artery, again only 
14.5% of the activity was found in the liver after 1 h (Table 1), and the systemic distribution of 
label was not distinguishable from that obtained with intravenous injection of pertechnetate. 
Intravenous injection of Tc99m-pertechnetate into rabbits bearing VX2 implants in 
their livers produced images with a noticeable shadow (isotope deficit) at the site of the 
tumour implant compared to the rest of the liver (Fig 1B). Retention of Tc99m-pertechnetate 
label by the liver hosting a tumour was similar to a normal liver; 12.3% of the total radioactivity 
at 1 h post injection (Table 1). 
By contrast, hepatic artery instillation of Tc99m-pertechnetate into rabbits hosting a 
VX2 liver tumour showed in all cases (n = 7) a prominent focal area of radioactivity in the liver 
persisting through to at least 1 h post instillation (Fig 1C), so that on excising the liver and 
imaging separately the percentage of total activity retained in the liver was clearly higher than 
in normal rabbits (26.4%; see Table 1). Furthermore there was a considerable accumulation 
of radiolabel in the tumour (Fig 1D); 28.9% of the isotope retained by the whole liver (Table 1), 
as estimated by applying a region of interest to the image, which usually results in an 
underestimate.  Since pertechnetate can potentially be internalised in cells by the expression 
of a membrane transport system known as the sodium iodide symporter (NIS), we tested the 
effect of prior intravenous administration of sodium perchlorate as a specific competitive 
inhibitor [22]. Preadministration of perchlorate strongly attenuated thyroid uptake of Tc-99m-
pertechnetate but only partially affected liver tumour uptake (Table 1) and did not prevent 
clear definition of liver tumours in imaging (see Fig 1E). Since polycations have been shown 
to increase vascular permeability in the lungs [23], we also tested the effect of intra-hepatic 
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artery instillation of PDL (150 µg) 15 min before instilling the Tc99m-pertechnetate in the 
same catheter; this pretreatment did not increase the retention of label in the liver or the 
tumour (not shown). 
Biodistribution of colloidal FL 
Intravenous injection of untreated FL showed rapid uptake and concentration in the 
reticuloendothelial system (liver, spleen and bone marrow; RES) as reported previously [15]. 
Imaging of the excised liver at 1 h post injection showed that the accumulated radioactivity 
was generally dispersed throughout the lobes of the organ, and accounted for approximately 
80% of the total radioactivity administered (Table 2). This figure was higher than our previous 
estimate of 60% made using a region of interest on the liver image in the intact animal [15]. 
When FL was administered by hepatic artery instillation, the whole body image and excised 
liver image were closely similar to those obtained after intravenous injection of FL, but the 
isotope activity retained in the liver at excision 1 h post instillation was higher, over 90% of the 
total dose administered (Table 2). 
Intravenous injection of untreated FL into rabbits bearing VX2 implants in their livers 
showed rapid uptake of label by the liver as in normal rabbits, but on imaging the excised liver 
at 1 h post injection it was evident that there was a noticeable shadow (isotope deficit) at the 
site of the tumour implant compared to the rest of the liver (Figs 2A,B). When the FL was 
instilled via the hepatic artery, liver uptake was as strong as seen in a normal liver (93.7%; 
Table 2). In 2 out of 5 of these cases there was a noticeable arc of activity proximal to the 
main arterial entry or even a complete ring of activity around the site of the tumour, but these 
features did not have a remarkably higher count per pixel than some other normal areas of 
the same liver (Figs 2C,D). 
Biodistribution of cationised colloidal FL 
It has been suggested that nanoparticles with a positively charged surface 
are more readily taken up by endothelium in the vasculature of a tumour [24,25]. Thus we 
tested the effect of cationising FL on its uptake into livers and liver tumours following hepatic 
artery instillation. FL was cationised with surface coatings of PS, PDL and CTH [15,19]. 
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These surface coatings did not change the strong liver retention of nanoparticles after arterial 
instillation (Table 2). Increased tumour uptake of nanoparticles was seen in a minority of 
cases after coating with PS and PDL (3 out of 10 cases), but this could have been merely due 
to larger tumour size; a detailed study was not done. However coating with CTH consistently 
produced a pronounced increase in tumour uptake of isotope, so that the tumour was often 
readily visible on imaging of the intact animal (Fig 3A) and in every case (n=8) featured 
prominently in the excised liver (Fig 3B). Radiolabel was consistently concentrated at the 
periphery of tumours, sometimes appearing as a continuous bright ring encircling the actual 
tumour mass (Fig 3B). Of the different liver tumour imaging methods tested in this study, 
intra-arterial administration of CTH coated FL produced the highest proportion of the 
administered dose accumulated at tumour sites (17.5%; Table 3), while 95% of the total 
administered dose was still retained by the host liver.  
Since marked accumulation of CTH/FL at tumour sites was evident in gamma camera 
imaging, we investigated further at the histological level. In standard haematoxylin and eosin 
stained sections, it was not possible to find any carbon particles after hepatic artery 
installation of uncoated FL, even at high power magnification; the uniform distribution of the 
microgram quantities of nanoparticles into the rabbit livers (mean weight 117 g; n=23) 
produced dilution to the point where they were not detectable. By contrast, CTH/FL that was 
strongly accumulated in liver tumours as seen by gamma camera imaging (Fig 3B), could also 
be found on microscopic examination of sections from the same liver (Fig 3C). Clusters of 
black carbon particles were clearly visible accumulated in microvessels located in close 
proximity to the edge of the tumour, but were absent in vessels further away from the tumour, 
or within the nests of tumour cells (Fig 3C). In some cases extravascular macrophages 
contained some carbon particles, but it was clear that the majority of nanoparticles 
accumulated in intravascular clusters without extravasation. 
The mechanism responsible for the liver tumour accumulation of CTH/FL was 
investigated using similar inhibition methods to those we previously used in lung perfusion 
studies [15,19]. Unlike accumulation of CTH/FL on heparan sulphate in the capillary network 
of normal rabbit lungs, the uptake of CTH/FL in rabbit VX2 liver tumours was not abolished by 
prior intravenous injection of potentially competing polycations; tumours were still clearly 
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visible in livers from rabbits that had been preinjected with PS (Fig 4A) and PDL (Fig 4B), and 
the tumours were also still labelled following pretreatment of the rabbit with intravenous 
heparinase [19] (not shown). Labelling of tumour was also still clearly evident even when the 
CTH/FL preparation was treated with heparin in vitro prior to intra-arterial instillation (Fig 4C). 
The percentage of CTH/FL label present at tumour sites in all of these inhibition tests was not 
outside the range for the tumours in Table 3. 
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Discussion 
 A detailed study of the liver uptake of soluble Tc-99m pertechnetate and Tc99m 
radiolabelled nanoparticles (FL) was made in rabbits following administration by both 
intravenous and intra-arterial (common hepatic artery) routes. Uptake from this set of 
administrations in normal rabbits was then compared with the uptake obtained after 
administration to rabbits bearing a model liver tumour, the transplantable rabbit VX2 
carcinoma. This provided data for each form of the radiolabel on the accumulation within the 
liver compared to the systemic distribution, and on the uptake of label by a tumour compared 
to the normal liver tissue of the host. 
While soluble Tc-99m as pertechnetate was widely distributed in the body following 
intravenous injection, with some accumulation in the thyroid and kidneys, FL was rapidly 
taken up by the reticuloendothelial system, as shown previously [15]. The presence of a VX2 
tumour in the liver showed as a negative area of uptake after intravenous injection of either 
pertechnetate or FL. The necrotic centre of the tumour may have produced an area of less 
perfusion for soluble isotope, while in the case of FL the lack of Kupffer cell function in the 
tumour compared to the liver may have reduced active accumulation of the nanoparticles.  
In rabbits hosting a liver VX2 implant, there were notable differences when 
pertechnetate and FL were administered arterially; pertechnetate showed unexpectedly high 
and persistent signal in the tumour, presumably due to the highly fenestrated new arterial 
vessels produced during tumour angiogenesis under the influence of tumour cytokines [26]. 
Active uptake of pertechnetate has been noted before in other tumours [27, 28], where it has 
been shown to be due to endogenous iodide symporter (NIS) expression, but in the case of 
VX2 liver tumours we found that while a competitive inhibitor of the NIS (perchlorate) 
prevented uptake of pertechnetate in the thyroid, it did not prevent pertechnetate uptake by 
the VX2 tumour in the liver. Permeability of the liver arterial system to pertechnetate was 
unaffected by PDL, unlike the increase in permeability induced in the lungs by polycations, 
shown by Dull et al [23] to be mediated by endothelial heparan sulphate. 
Arterial administration of FL showed some concentration of label around the tumour 
site in a minority of cases, presumably also due to the increased vascularity following 
angiogenesis, but this was not as consistent or pronounced as in the case of pertechnetate, 
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suggesting the nanoparticles may be too large to extravasate [29]. However when the FL was 
surface cationised by CTH, there was a consistent and marked increase in accumulation at 
the tumour site. In at least two cases this accumulation was visible both in gamma camera 
imaging as well as in histology, when accumulations of black carbon were found inside 
microvessels close to the edge of tumour cell nests, but not in vessels further away.  
Since accumulation of CTH/FL at liver tumours was not affected by prior treatment of 
the host rabbits with PDL or heparinase, or even by treatment of the CTH/FL with heparin in 
vitro prior to intra-arterial instillation, it appears that the mechanism involved is not a simple 
charge interaction with endothelial heparan sulphate as we found previously in the lungs 
[15,19]. Significantly, there was also no effect on liver tumour accumulation of CTH/FL when 
the host was pretreated with PS. These observations together suggest that a more specific 
interaction of CTH is involved, since the protamines are a very similar group of cationic 
nuclear proteins to histones. One possibility would be that CTH is binding to Toll-like 
receptors on the angiogenic endothelium induced by cytokines at tumour sites [30].  The 
results also showed that accumulation of nanoparticles at a tumour site does not necessarily 
imply extravasation has occurred; at histology we found accumulation of CTH/FL within 
microvessels at the edge of liver tumours but not outside microvessels or within the nests of 
tumour cells. Clearly this has significant implications not only for delivery of cytotoxic drugs to 
tumour cells but also for tumour cell targeting dependent on monoclonal antibody coated 
nanoparticles actually reaching their cognate target antigens on tumour cells. The data 
instead supports the notion that targeting of angiogenic endothelium at tumour sites is a more 
attractive strategy. 
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Conclusion 
 
 Our results with a model tumour system hosted in an internal organ provide useful 
insight into the tissue penetration of different isotope preparations following administration by 
the intravenous and intra-arterial routes, further illustrating the difference in tumour 
accessibility. Uptake of soluble pertechnetate and FL nanoparticles into tumours from the 
venous circulation was uniformly absent, whereas both preparations were accumulated in the 
immediate periphery of liver tumours following intra-arterial instillation, even despite their 
large difference in size. Effective dosing of liver tumours with a nanoparticle agent is thus 
shown to have considerably more chance of success when administered by the arterial route*. 
Our isotope imaging and histological findings with histone-coated nanoparticles further 
suggest that this formulation can specifically accumulate nanoparticles in angiogenic 
microvessels at the growth zone peripheral to tumours. 
 
*Footnote: During preparation of this manuscript some similar findings were reported by Tian 
et al [31].  
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Figure captions 
 
Figure 1. Tc99m-pertechnetate biodistribution in normal rabbits and in rabbits with VX2 
tumour implants. The gamma camera images show radioisotope activity in the liver of a 
normal rabbit (Fig 1A) and livers of rabbits hosting a VX2 implant (Figs 1B,C,D,E), 1 h after 
administration of Tc99m-pertechnetate (130 MBq) by intravenous injection (3 mL; Figs 1A,B) 
or intra-arterial instillation (5 mL; Figs 1C,D,E). Organs in Fig 1A are labelled as thyroid (T), 
heart (H), liver (L) kidneys (K) and bladder (B). Note the negative image of the VX2 tumour 
(indicated by V) in the liver in Fig 1B, and compare with the positive imaging of the tumour (V) 
in the intact rabbit in Fig 1C, and in the excised liver from Fig 1C shown in Fig 1D. Positive 
imaging of the tumour in a rabbit by intra-arterial Tc99m-pertechnetate was not abolished (V 
in Fig 1E) by prior intravenous injection of sodium perchlorate (3 mg/kg), an inhibitor of the 
active transport of iodide and pertechnetate [22]. Images were acquired with a GE Hawkeye 
Infinia gamma camera. 
 
Figure 2. Uptake of FL in rabbit livers hosting VX2 tumours. The gamma camera images 
show radioisotope activity in the excised livers of rabbits 1 h after intravenous injection (3 mL; 
Figs 2A and 2B) and intra-arterial (5 mL; Figs 2C and 2D) instillation of untreated FL (130 
MBq). Note the negative image of the tumours indicated by V in Figs 2A and 2B, and contrast 
with the positive signal obtained at the tumours in Figs 2C and 2D. Images were acquired with 
a Siemens Diacam gamma camera. 
 
Figure 3. Uptake of histone-coated FL in rabbit liver hosting VX2 tumour. The gamma camera 
images show radioisotope biodistribution in an intact rabbit (Fig 3A) and in the corresponding 
excised liver from this rabbit (Fig 3B), 1 h after intra-arterial instillation of CTH/FL (5 mL, 130 
MBq). Note the strong labelling of the liver region hosting the tumour visible in the intact 
animal and in the excised liver (tumour indicated by V). Images 3A and 3B were acquired with 
a Siemens Diacam gamma camera. Figure 3C shows a haematoxylin and eosin stained 
section of the liver VX2 tumour from the same rabbit liver. Note accumulations of black 
carbon nanoparticles in the microvessels at the edge of a nest of tumour cells. Magnification 
x200. 
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 Figure 4. Inhibition tests of tumour CTH/FL uptake. The excised liver images shown are from 
rabbits injected intravenously with protamine sulphate (1 mg/kg) (Fig 4A) and poly-D-lysine (1 
mg/kg) (Fig 4B), 10 min prior to intra-arterial instillation of CTH/ FL (5 mL, 130 MBq). Note 
that tumours were labelled in each of these pretreated rabbits (tumours indicated by V). When 
the CTH/FL preparation was treated with heparin (1 mg/mL) in vitro before intra-arterial 
instillation, the tumour was still strongly labelled  (Fig 4C). Images in Figs 4A-C were acquired 
with a GE Hawkeye Infinia gamma camera. 
 
 
 
 
 Tables 
 
 
 
Table 1: Tc99m-Pertechnetate uptake in normal rabbit livers and livers with VX2 implants 
 
 
 
Rabbit Admin Route 
Mean Activity in Liver 
(%Total) 
Number of 
Tests 
Range (%) 
Normal 
IV 12.9  2 10.0 - 15.8 
IHA 14.5  2 14.5 – 14.5 
VX2 
IV 12.3  2 12.1 – 12.5 
IHA 26.4  5 17.6 – 34.6 
IV perchlorate then 
IHA pertechnetate 
19.2 2 16.4 – 22.0 
 
 
 
Retention of radioisotope activity in the livers of normal rabbits and livers of rabbits hosting a 
VX2 implant, 1 h after administration of Tc99m-pertechnetate (130 MBq) by intravenous 
injection (3 mL; IV) or intra-arterial instillation (5 mL; IHA). Activity in the excised liver image 
was compared to the body image after removal of the liver, and corrected for background in 
the corresponding detection fields. For two tumour rabbits, sodium perchlorate (3 mg/kg) was 
injected intravenously before IHA instillation of the isotope, to test the role of symporter in 
tumour retention of pertechnetate [22]. 
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Table 2: FL uptake in normal livers and livers with VX2 implants 
 
 
 
Rabbit Admin Route 
Mean Activity in Liver 
(%Total) 
Number of 
Tests 
Range (%) 
Normal 
IV 79.1 3 75.8 – 81.2 
IHA 91.5  5 89.4 – 94.4 
VX2 
IV 74.3 2 73.0 – 75.7 
IHA 93.7  5 91.5 – 95.3 
IHA PS/FL 92.9 2 90.7 – 95.1 
IHA PDL/FL 96.2 8 95.0 – 97.1 
IHA CTH/FL 95.0 9 87.4 – 98.0 
 
 
 
Retention of radioisotope activity in the liver of normal rabbits and livers of rabbits hosting a 
VX2 implant, 1 h after administration of FL nanoparticles (130 MBq) by intravenous injection 
(3 mL; IV) or intra-arterial instillation (5 mL; IHA). Activity in the excised liver image was 
compared to the body image after removal of the liver, and corrected for background in the 
corresponding detection fields. FL was tested either untreated or surface cationised with 
protamine sulphate (PS), poly-D-lysine (PDL) or calf thymus histones (CTH). 
 
 
  
 
 
 
 
 
Table 3: Liver and VX2 tumour uptake of intra-arterial pertechnetate and CTH/FL 
 
 
 
 
Measure 
Tc99m-Pertechnetate 
n = 7 
CTH/FL 
n = 8 
% ID in Liver 24.4 +/- 7.7 94.7 +/- 3.5 
% Liver activity in tumour 28.9 +/- 6.8 18.6 +/- 5.0 
% ID in tumour 7.2 +/- 3.4 17.5 +/- 5.0 
Estimated % ID/g liver* 0.15 0.66 
Estimated % ID/g tumour** 2.5 6.0 
Estimated ratio tumour/liver 17 9.1 
 
*Mean liver weight = 117 +/- 24 g (n = 23) 
 
** Mean tumour weight = 2.9 +/- 1.9 g (n = 41) 
 
 
Retention of radioisotope activity in the livers of rabbits hosting a VX2 implant, 1 h after 
administration of Tc99m-pertechnetate or CTH/FL nanoparticles (5 mL, 130 MBq) by intra-
arterial instillation (IHA). The percentage of the administered dose (ID) in the liver was 
obtained from the image of the excised liver and the image of the body after removal of the 
liver, and the percentage of ID retained in the tumour was estimated by drawing a region of 
interest over the tumour in the image of the excised liver.  Mean values corrected for 
background in the corresponding detection fields are shown with the standard deviation. The 
estimate shown for % ID/g liver is based on a mean weight of 117 g obtained for 23 excised 
livers, while the estimated % ID/g tumour is calculated from measurements of the largest and 
smallest diameters of 41 sectioned tumours from excised livers. 
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